Interchangeability Evaluation of Multisource Ibuprofen Drug Products Using Biowaiver Procedure

The WHO biowaiver procedure for BCS Class II weak acids was evaluated by running two multisource IR ibuprofen drug products (Ibuprofen, 200 mg tablets, Tatchempharmpreparaty, Russia and Ibuprofen, 200 mg tablets, Biosintez, Russia) with current Marketing Authorizations (i.e. in vivo bioequivalent) t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shohin, I. E., Kulinich, J. I., Vasilenko, G. F., Ramenskaya, G. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374563/
https://www.ncbi.nlm.nih.gov/pubmed/22707831
http://dx.doi.org/10.4103/0250-474X.95643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374563/
https://www.ncbi.nlm.nih.gov/pubmed/22707831
http://dx.doi.org/10.4103/0250-474X.95643

Ejemplares similares